...
首页> 外文期刊>Chemical and Pharmaceutical Bulletin >1,4-Benzoxazine-3(4H)-ones as Potent Inhibitors of Platelet Aggregation: Design, Synthesis and Structure–Activity Relations
【24h】

1,4-Benzoxazine-3(4H)-ones as Potent Inhibitors of Platelet Aggregation: Design, Synthesis and Structure–Activity Relations

机译:1,4-Benzoxazine-3(4H)-作为血小板聚集的强抑制剂:设计,合成和结构-活性关系

获取原文

摘要

A series of novel potentially platelet aggregation-inhibiting 1,4-benzoxazine-3(4 H )-one derivatives was designed and synthesized through Smiles rearrangement, reduction and acetylation reactions. The antiaggregatory activities of the target molecules on arterial blood samples from rabbits, expressed by IC50 values (μM), were then evaluated in vitro against ADP induced platelet aggregation. The favorable IC50 values of compound 8c (IC50=8.99?μM) and 8d (IC50=8.94?μM) indicated that these two compounds were the most potent molecules among all the synthesized compounds. A detailed molecular docking study to explore the interaction of compounds 8c and 8d with GP IIb/IIIa receptor showed that they these two compounds were docked into the active site of GPIIb/IIIa receptor. These results suggest that the 1,4-benzoxazine-3(4 H )-one derivatives are promising lead compounds to develop new platelet aggregation inhibitors.
机译:通过Smiles重排,还原和乙酰化反应设计并合成了一系列抑制血小板聚集的新型1,4-苯并恶嗪-3(4 H)-one衍生物。然后用IC 50 值(μM)表示目标分子对兔动脉血样品的抗聚集活性,以对抗ADP诱导的血小板聚集。化合物8c(IC 50 = 8.99?μM)和8d(IC 50 = 8.94?μM)的有利IC 50 值表明这些在所有合成的化合物中,两种化合物是最有效的分子。一项详细的分子对接研究探讨了化合物8c和8d与GP IIb / IIIa受体的相互作用,结果表明,这两种化合物已对接至GPIIb / IIIa受体的活性位点。这些结果表明1,4-苯并恶嗪-3(4 H)一衍生物是有前途的铅化合物开发新的血小板聚集抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号